

## Letter to the Editor

### In Reply to Dr Connors et al

To the Editor:

We are very grateful to read the comments from Connors et al<sup>1</sup> on our article.<sup>2</sup> Amatoxin poisoning is a medical emergency characterized by hepatotoxicity, encephalopathy, coma, and death. The main amatoxins are  $\alpha$ ,  $\beta$ , and  $\gamma$  amanitins. They inhibit eukaryotic RNA polymerase II, causing transcriptional arrest and affecting metabolically highly active cells such as hepatocytes and kidney cells. Amanita toxin has a molecular weight of 373 to 990 Da, is water soluble with  $0.3 \text{ L}\cdot\text{kg}^{-1}$  Vd, is 0.3% protein binding, and has 2.7 to  $6.2 \text{ mL}\cdot\text{min}^{-1}\cdot\text{kg}^{-1}$  endogenous clearance.<sup>1</sup>

Although oral decontamination with activated charcoal, intravenous hydration, N-acetyl cysteine, silibinin, and penicillin are recommended in the standard treatment approach, these treatments are often insufficient because symptoms occur after a relatively long and obscure incubation period. Extracorporeal treatments (eg, conventional hemodialysis [HD], continuous renal replacement therapies [CRRT], plasmapheresis, hemoperfusion [HP], extracorporeal albumin dialysis) can be used to remove toxic compounds from the body for supportive treatment in clinical emergency situations when specific treatment is insufficient.<sup>3,4</sup> The lack of well-designed studies on the optimal method of extracorporeal removal of toxic compounds, thus staying at a lower level of evidence, is a major problem.

The more expeditiously toxins are removed, the less chance major toxicity will ensue<sup>5</sup>; thus, extracorporeal treatment may be an efficacious alternative treatment modality. In general, clearance of dialysable substances is lower with CRRT than with conventional HD<sup>6</sup> owing to slower flow rates, and although HD is readily available in most hospitals, many are not capable of delivering CRRT, HP, plasmapheresis, or extracorporeal albumin dialysis. One of the problems with toxin removal by dialyzers and HP devices is that their effects on pharmacokinetic parameters other than simple clearance measurements are largely unknown. This problem can also be experienced in newly developed dialyzers (mid-cutoff, high-cutoff). However, new studies can be instructive.

Owing to the urgent nature of amatoxin poisoning treatment and uncertainties in resolving potential complications, we may never be able to find well-designed, evidence-based studies to guide us. In dealing with these controversial issues, we must continue to use less than ideal evidence and our own experience to guide our decision-making.

Bülent Huddam, Prof. Dr.  
Alper Alp, Assist. Prof. Dr.  
Department of Nephrology  
Faculty of Medicine  
Mugla University  
Mugla, Turkey

İsmail Kırılı, Assist. Prof. Dr.  
Mehmet Yılmaz, MD  
Aytuğ Çağırtekin, MD  
Department of Internal Medicine  
Faculty of Medicine  
Mugla University  
Mugla, Turkey

Hakan Allı, Assoc. Prof. Dr.  
Department of Biology  
Faculty of Science and Arts  
Mugla University  
Mugla, Turkey

Sultan Edebalı, MD  
Department of Internal Medicine  
Faculty of Medicine  
Mugla University  
Mugla, Turkey

### References

1. Connors NJ, Gosselin S, Hoffman RS. Regarding median cut-off membrane can be a new treatment tool in *Amanita phalloides* poisoning. *Wilderness Environ Med*. In press.
2. Huddam B, Alp A, Kırılı İ, Yılmaz M, Çağırtekin A, Allı H, et al. Medium cut-off membrane can be a new treatment tool in *Amanita phalloides* poisoning. *Wilderness Environ Med*. 2021;32(2):192–7.
3. Goldfarb DS. Principles and techniques applied to enhance the elimination of toxic compounds. In: Goldfrank LR, Smith SW, Lewin NA, Howland MA, Hoffman RS, Nelson LS, eds. *Goldfrank's Toxicologic Emergencies*. 11th ed. New York: McGraw-Hill; 2019:90–101.
4. Ye Y, Liu Z. Management of *Amanita phalloides* poisoning: a literature review and update. *J Crit Care*. 2018;46:17–22.
5. King JD, Kern MH, Jaar BG. Extracorporeal removal of poisons and toxins. *Clin J Am Soc Nephrol*. 2019;14(9):1408–15.
6. Sigler MH, Teehan BP, Daugirdas JT, Ing TS. Slow continuous therapies. In: Daugirdas JT, Blake PG, Ing TS, eds., *Handbook of Dialysis*. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001:199–230.